resVida® Shows Cardio Benefits

PARSIPPANY, N.J.DSM Nutritional Products announced data from two analyses of the first human study of resVida® trans-resveratrol that were presented at the 4th International Conference on Polyphenols and Health (ICPH) in Yorkshire, England, Dec. 7 to 10, 2009, and the Nutrition Society of Australia (NSA) and Nutrition Society of New Zealand (NSNZ) Joint Annual Scientific Meeting in Newcastle, NSW, Dec. 8 to 11, 2009.

The first analysis from this study presented by Narelle Berry, Ph.D., at ICPH aimed to determine whether consuming resVida trans-resveratrol could enhance flow mediated dilation (FMD) of the brachial artery and whether there is a dose-response relationship between resVida trans-resveratrol and FMD. The second study analysis presented by Rachel Wong, B.S., at the NSA and NSNZ Joint Annual Scientific Meeting investigated whether consuming resVida trans-resveratrol in small doses would enhance FMD and calm a rise in blood pressure in response to sub-maximal exercise and whether there was a dose-response relationship for these improvements.

The study participants included 19 overweight or obese untreated hypertensive men and post-menopausal women randomly assigned to consume placebo and three single doses of resVida trans-resveratrol (30, 90, 270 mg) at weekly intervals.

Both study analyses found that there was a significant effect of trans-resveratrol supplementation on FMD (P=0.006) with FMD increasing from 3.9 +/- 0.8 after placebo to 7.6 +/- 1.6 percent at 270 mg. FMD was also linearly related to plasma trans-resveratrol concentration. These preliminary data suggest resVida trans-resveratrol is an active mediator of the purported cardiovascular health benefits of red wine and grape consumption. The second study also reported they did not find a treatment effect with resVida trans-resveratrol on the blood pressure response to exercise.